Definitive Radiotherapy for Oligometastatic and Oligoprogressive Thyroid Cancer: A Potential Strategy for Systemic Therapy DeferralStephanie O. Dudzinski, Matthew S. Ning, Maria E. Cabanillas et al.|Journal of the National Comprehensive Cancer Network|2024Cited by 5
Reimagining the Therapeutic Approach for Anaplastic Thyroid Cancer: The Roadmap to a CureMaria E. Cabanillas, Mark Zafereo, Marie‐Claude Hofmann et al.|Thyroid|2025Cited by 5
Cobimetinib plus atezolizumab for <i>RAS</i> and <i>NF</i>1/2-mutated poorly differentiated thyroid carcinoma.Sarah Hamidi, Ramona Dadu, Naifa L. Busaidy et al.|Journal of Clinical Oncology|2024Cited by 4
Real-World Experience with Lenvatinib plus Pembrolizumab in Metastatic <i>BRAF</i> Wild-Type Anaplastic Thyroid CarcinomaSarah Hamidi, Ramona Dadu, Danica M. Vodopivec et al.|Thyroid|2026Cited by 2